CME: Advances in Severe Asthma: Highlights from ACAAI 2019

Advances in Severe Asthma: Highlights from ACAAI 2019

Advances in Severe Asthma: Highlights from ACAAI 2019

Why do patients still experience poorly controlled asthma despite tremendous progress in therapy? Data from ACAAI 2019 may have the answer.

Available credits: 0.25

Time to complete: 15 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Despite recent advances in management, many patients still experience uncontrolled or poorly controlled asthma. To keep you up to date on those emerging treatment options, this expert discussion will review patient- and practice-focused data presented during ACAAI 2019.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Nicola A. Hanania, MD, MS
    Associate Professor
    Baylor College of Medicine
    Houston, TX

    Consulting Fees: AstraZeneca, Genentech, Genzyme, GlaxoSmithKline, Novartis, Regeneron, Sanofi
    Contracted Research: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi Genzyme

    Reynold A. Panettieri, Jr., MD
    Professor of Medicine
    Robert Wood Johnson Medical School
    Vice Chancellor, Clinical & Translational Science
    Director, Rutgers Institute for Translational Medicine and Science
    Rutgers University
    New Brunswick, NJ
    Emeritus Professor of Medicine, University of Pennsylvania
    Philadelphia, PA

    Consulting Fees: AstraZeneca, Avillion, Boehringer-Ingelheim, Equillium, Medimmune, RIFM, Sanofi/Regeneron, Theravance
    Contracted Research:  AstraZeneca, Equillium, Genentech, Medimmune, RIFM, OncoArendi, Teva, Theratrophix
    Other: AstraZeneca, Genentech, Sanofi/Regeneron

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Feidel, PhD has nothing to disclose.
    • Jennifer Caudle, DO has nothing to disclose.
    • William A. Mencia, MD has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:
    1. Identify poorly controlled asthma patients to intensify treatment where appropriate
    2. Demonstrate an improved understanding of current and emergent science of asthma control

  • Target Audience

    This activity is designed to meet the educational needs of pulmonologists, allergists, pediatricians, primary care physicians, nurse practitioners, physician assistants and other members of the care team who see and treat patients with asthma.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    GLC designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free